Keros Therapeutics (KROS) is a clinical-stage biopharmaceutical company. George Tsilis discusses KROS as the company focuses on developing treatments for hematological and musculoskeletal disorders. He talks about how KROS presented data from ongoing Phase 2 clinical trials of Ker-050 and Ker-047 at a healthcare conference. Tune in to find out more about the stock market today.
Market On Close
14 Dec 2022
SHARE
Morning Trade Live
15 Sep 2023
Trading 360
13 Oct 2023
Market On Close
24 Oct 2023
The Watch List
02 Oct 2023
Market On Close
30 Nov 2023
Trading 360
09 Nov 2023